@article{98adaeead76f412a8434577c47a69ab6,
title = "Complete blood count derived inflammatory biomarkers and the level of anti-SARS-CoV-2 NAb and S-RBD IgG among cancer survivors receiving COVID-19 vaccines",
abstract = "Background: In the era of coronavirus disease 2019 (COVID-19), it is mandatory to identify vulnerable people with cancers as they have impaired immune system that can lead to high mortality. This study analyzes the complete blood count (CBC) derived inflammatory biomarkers and the level of anti-SARS-CoV-2 neutralizing antibody (NAb) and spike protein{\textquoteright}s receptor-binding domain immunoglobulin G (S-RBD IgG) among cancer survivors. Methods: A cross-sectional study was conducted in patients with either solid or hematological cancers who had received two-doses of COVID-19 vaccinations within six months. Results: From 119 subjects, the COVID-19 vaccines demonstrated laboratory efficacy (median NAb=129.03 AU/mL; median S-RBD IgG=270.53 AU/mL). The seropositive conversion of NAb reached 94.1% and S-RBD IgG reached 93.3%. Additionally, the S-RBD IgG had very weak correlation with absolute monocyte count (R=-0.185; pvalue=0.044). The NAb also had very weak correlation with leukocyte (Kendall{\textquoteright}s tau-b (τb)=-0.147; p-value=0.019), absolute neutrophil count (τb=-0.126; p-value=0.044), absolute eosinophil count (τb=-0.132; p-value=0.034). Conclusion: The seropositivity rate of anti-SARS-CoV-2 NAb and S-RBD IgG were significantly high. However, the CBC derived inflammatory biomarkers had poor correlation with anti-SARS-CoV-2 NAb and S-RBD IgG. Thus, antiSARS-CoV-2 NAb and S-RBD IgG are currently the only reliable markers for measuring the COVID-19 vaccine efficacy which should be widely accessible.",
keywords = "cancer, complete blood count, COVID-19, inflammatory biomarkers, vaccine",
author = "Andhika Rachman and Anggraini Iriani and Cosphiadi Irawan and Lugyanti Sukrisman and Wulyo Rajabto and Mulansari, {Nadia Ayu} and Lubis, {Anna Mira} and Findy Prasetyawaty and Rahmat Cahyanur and Dimas Priantono and Rumondor, {Bayu Bijaksana} and Rachelle Betsy and Samuel Juanputra",
note = "Funding Information: Author contributions: AR & AI: conception & design; CI, LS, WR, & NAM: interpreted the results; AML, FP, & RC: performed the statistical analysis; & DP, BBR, RB, & SJ: drafted the manuscript; and Rachman A supervised the study. All authors read and approved the final manuscript. All authors have agreed with the results and conclusions. Funding: This study was funded by Dr. Cipto Mangunkusumo National Central General Hospital{\textquoteright}s grant program “Hibah Riset Operasional RSCM” (grant number: LB.01.02/2.6/0668/2021). Acknowledgements: The authors would like to thank all participants for their involvement. Ethical statement: Authors stated that the ethical approval for this study was granted by The Ethics Committee of The Faculty of Medicine, Universitas Indonesia (ethical approval number: KET-999/UN2.F1/ETIK/PPM.00.02/2021). Declaration of interest: No conflict of interest is declared by authors. Data sharing statement: Data supporting the findings and conclusions are available upon request from the corresponding author. Publisher Copyright: {\textcopyright} 2023 by Author/s and Licensed by Modestum. All rights reserved.",
year = "2023",
month = apr,
doi = "10.29333/ejgm/12851",
language = "English",
volume = "20",
journal = "Electronic Journal of General Medicine",
issn = "1304-3889",
publisher = "Modestum Ltd.",
number = "2",
}
